ReviewCurrent anesthesiology reports2018
Sugammadex: Appropriate Use in the Context of Budgetary Constraints.
Review in Current anesthesiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04762420 (Sugammadex Dosing), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sugammadex Dosing: Anaesthesiologist Clinical Perception Versus Quantitative Monitoring
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- General anesthesia with spontaneous breathing and laryngeal mask airway intubation combined with peripheral nerve block in orthopedic surgery: a retrospective study.Frontiers in medicine · 2025Article
- Quantitative Monitoring Maximizes Cost-Saving Strategies When Antagonizing Neuromuscular Block With Sugammadex.Cureus · 2024Article
- Unexpected delayed reversal of rocuronium-induced neuromuscular blockade by sugammadex: A case report and review of literature.World journal of clinical cases · 2022Article
- Perioperative Efficiency of Sugammadex Following Laparoscopic Cholecystectomy in Clinical Practice.Ochsner journal · 2022Article
- Sugammadex versus neostigmine for neuromuscular blockade reversal in outpatient surgeries: A randomized controlled trial to evaluate efficacy and associated healthcare cost in an academic center.Frontiers in medicine · 2022Article
- Hawthorne Effect: More Than Just Telephones.Ochsner journal · 2022Article
- Comparison of the Time to Extubation and Length of Stay in the PACU after Sugammadex and Neostigmine Use in Two Types of Surgery: A Monocentric Retrospective Analysis.Journal of clinical medicine · 2021Article
- Utilization Patterns of Perioperative Neuromuscular Blockade Reversal in the United States: A Retrospective Observational Study From the Multicenter Perioperative Outcomes Group.Anesthesia and analgesia · 2020Observational
- Advantages and pitfalls of clinical application of sugammadex.Anesthesia and pain medicine · 2020Review
- Current use of neuromuscular blocking agents and antagonists in Korea: a 2018 survey.Anesthesia and pain medicine · 2019Article
- Sugammadex compared with Neostigmine/Glycopyrrolate: An Analysis of Total PACU Time, Responsiveness, and Potential for Economic Impact.Innovations in pharmacy · 2019Article
- Incremental sugammadex dosing: Fine-tuning anesthesia for thyroidectomy under intraoperative neurophysiological monitoring.Journal of anaesthesiology, clinical pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review is to assess how sugammadex impacts postoperative residual curarization using appropriate doses based on neuromuscular transmission monitoring and whether the advantages of sugammadex versus neostigmine outweigh its higher cost. RECENT
findingsAn accurate assessment of neuromuscular blockade with monitoring is necessary before selecting neostigmine versus sugammadex for reversal at the end of surgery to overcome incomplete neuromuscular recovery. The main advantages of sugammadex over neostigmine are its predictability and its ability to extend the range of blockade reversal. The cost of sugammadex is greater when higher doses of sugammadex are required for antagonism of deep block. Sugammadex probably has the potential to be cost-effective compared with neostigmine if its time savings are put to productive use in clinical practice. However, to date, the economic benefits of the drug are unknown. SUMMARY: With sugammadex, almost any degree of neuromuscular block can be antagonized within 2-3 min; neostigmine is the only reversal agent effective against benzylisoquinolines and can ideally be used for reversal of lower levels of residual paralysis. The performance of the more expensive sugammadex on improving patient outcomes may depend on several elements of clinical strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.